Craig-Hallum Initiates Coverage On BioLife Solns with Buy Rating, Announces Price Target of $29
Portfolio Pulse from richadhand@benzinga.com
Craig-Hallum analyst Matt Hewitt has initiated coverage on BioLife Solns (NASDAQ:BLFS) with a Buy rating and a price target of $29.
July 11, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioLife Solns has been given a Buy rating by Craig-Hallum analyst Matt Hewitt, with a price target of $29.
The Buy rating and price target of $29 announced by Craig-Hallum analyst Matt Hewitt is a positive signal for BioLife Solns. This could potentially attract investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100